Dr. Matthew Downham
Werdegang
Berufserfahrung von Matthew Downham
- Bis heute 12 Jahre und 4 Monate, seit Feb. 2013
Associate Director - Flu MSAT
AstraZeneca / MedImmune Ltd, UK
- 3 Jahre und 4 Monate, Okt. 2009 - Jan. 2013
Head of Toxicology then Global Animal Welfare Officer
Novartis Vaccines and Diagnostics Srl, ITALY
- 2 Jahre und 2 Monate, Aug. 2007 - Sep. 2009
Senior Manager, Preclinical & Early Clinical Development
MorphoSys AG, BRD
Initially managing the proprietary HuCAL® Gold derived human monoclonal antibody haematological malignancy project, primarily targeting multiple myeloma. Currently, management of the anti-inflammatory HuCAL GOLD® antibody project targeting RA, Asthma, COPD and MS. Driving the project in collaboration with the project teams through all aspects of the preclinical (non-GLP & GLP, in-vitro/vivo analysis), IP, business development, manufacturing (non-GMP/GMP), regulatory and clinical (GCP) phases.
- 1 Jahr und 10 Monate, Okt. 2005 - Juli 2007
Director, Preclinical Development
Bavarian Nordic GmbH, BRD
Directing the pre-clinical development department establishing and running in-vitro/vivo internal/external toxicology/pharmacology studies and clinical trial sample analysis, ensuring data quality and reporting on development of MVA-BN® viral vaccines for Smallpox, HIV, Measles and RSV. Additionally including the roles, Head of the GLP Animal Facility and Programme Director, Childhood Vaccines (Measles and RSV).
- 8 Jahre und 2 Monate, Aug. 1997 - Sep. 2005
Head of Non-Clinical Development
Protherics Plc, UK
R&D of novel peptide-conjugate vaccine, antibody fragment, antibody technology and enzyme therapeutics targeting a range of disease & antidote requirements. Considerable involvement in anti-hypertensive (Angiotensin), anti-metastasis (VEGF) conjugate vaccine and CPG2 enzyme rescue therapy development programmes, the latter for US & EU regulatory license applications.
- 3 Jahre, Apr. 1993 - März 1996
Post-Doctoral Research Fellow
Liverpool John Moores University, UK
Control of eukaryotic cell chaperone protein expression to enhance secretion of a therapeutic chimeric antibody. Included lab based experimentation; lecturing, tutoring, demonstrating, supervising & assessing biomolecular science degree (BSc & MSc) students.
Ausbildung von Matthew Downham
- 11 Jahre und 6 Monate, Apr. 2010 - Sep. 2021
European Registered Toxicologist
Royal Society of Biology, UK
- 11 Monate, Sep. 1996 - Juli 1997
Further & Higher Education Teaching
Bolton Institute, UK
Included lectureships (JMU & Hope University College both Liverpool, UK) teaching biochemistry, biotechnology and immunology.
- 3 Jahre und 5 Monate, Sep. 1989 - Jan. 1993
Biochemical Engineering
The University of Birmingham, UK
Immunoaffinity chromatography in biorecovery: application of recombinant DNA to a generic adsorption process. Sponsored by CellTech Ltd., Slough, UK.
- 3 Jahre und 11 Monate, Sep. 1985 - Juli 1989
Industrial Biology
London South Bank Polytechnic, UK
Included a research placement at Boehringer Mannheim GmbH (now Roche), Penzberg, Germany. Culturing eukaryotic cells in a variety of fermentation systems to optimise productivity of therapeutic monoclonal antibodies.
Sprachen
Englisch
Muttersprache
Deutsch
Fließend
XING – Das Jobs-Netzwerk
Über eine Million Jobs
Entdecke mit XING genau den Job, der wirklich zu Dir passt.
Persönliche Job-Angebote
Lass Dich finden von Arbeitgebern und über 20.000 Recruiter·innen.
22 Mio. Mitglieder
Knüpf neue Kontakte und erhalte Impulse für ein besseres Job-Leben.
Kostenlos profitieren
Schon als Basis-Mitglied kannst Du Deine Job-Suche deutlich optimieren.